PDF(Pubmed)
Abstract：
UNASSIGNED: Prostate cancer represents a major health concern worldwide, with the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and locally advanced prostate cancer posing a particular challenge. Rezvilutamide, a new androgen receptor antagonist from China, has shown early promise; however, its real-world effectiveness and safety profile require further evidence. This case series evaluates the preliminary clinical outcomes of rezvilutamide in combination with androgen deprivation therapy (ADT), focusing on PSA response and radiological findings across various stages of prostate cancer in four patients.
UNASSIGNED: Case 1 details a 68-year-old male with low-volume mHSPC who exhibited a positive therapeutic response, demonstrated by decreasing PSA levels and improved radiographic results, despite experiencing mild side effects related to the drug. Case 2 describes a 71-year-old male with high-volume mHSPC who had a favorable outcome, with no significant changes in tumor size or metastatic spread and no negative reactions to the drug. Case 3 involves a 55-year-old male with locally advanced prostate cancer, who saw a reduction in PSA levels and a small decrease in tumor volume, yet with ongoing bladder involvement. Genetic testing showed no significant mutations. Case 4 presents a 74-year-old male with extensive metastatic disease who initially responded to the treatment but later exhibited disease advancement and an ATM gene mutation, signaling a shift to metastatic castration-resistant prostate cancer (mCRPC). This finding underscores the crucial role of genetic testing in directing future treatment, with therapies such as olaparib or chemotherapy being advised.
UNASSIGNED: Rezvilutamide has shown a potential benefit in the management of mHSPC and locally advanced prostate cancer, generally with a mild safety profile. Initial positive responses, particularly in PSA decline and radiographic progression, are promising. Nevertheless, the varying responses, notably concerning genetic mutations, highlight the necessity for tailored treatment approaches. Due to the small cohort and brief follow-up period, more extensive research with larger populations and prolonged monitoring is essential to conclusively determine the benefits and safety of rezvilutamide. The utilization of genetic insights is key to refining treatment decisions and enhancing outcomes for patients with advanced prostate cancer.
UNASSIGNED: Case 1 details a 68-year-old male with low-volume mHSPC who exhibited a positive therapeutic response, demonstrated by decreasing PSA levels and improved radiographic results, despite experiencing mild side effects related to the drug. Case 2 describes a 71-year-old male with high-volume mHSPC who had a favorable outcome, with no significant changes in tumor size or metastatic spread and no negative reactions to the drug. Case 3 involves a 55-year-old male with locally advanced prostate cancer, who saw a reduction in PSA levels and a small decrease in tumor volume, yet with ongoing bladder involvement. Genetic testing showed no significant mutations. Case 4 presents a 74-year-old male with extensive metastatic disease who initially responded to the treatment but later exhibited disease advancement and an ATM gene mutation, signaling a shift to metastatic castration-resistant prostate cancer (mCRPC). This finding underscores the crucial role of genetic testing in directing future treatment, with therapies such as olaparib or chemotherapy being advised.
UNASSIGNED: Rezvilutamide has shown a potential benefit in the management of mHSPC and locally advanced prostate cancer, generally with a mild safety profile. Initial positive responses, particularly in PSA decline and radiographic progression, are promising. Nevertheless, the varying responses, notably concerning genetic mutations, highlight the necessity for tailored treatment approaches. Due to the small cohort and brief follow-up period, more extensive research with larger populations and prolonged monitoring is essential to conclusively determine the benefits and safety of rezvilutamide. The utilization of genetic insights is key to refining treatment decisions and enhancing outcomes for patients with advanced prostate cancer.
摘要：
前列腺癌是全球范围内的主要健康问题，转移性激素敏感型前列腺癌（mHSPC）和局部晚期前列腺癌的治疗构成了特殊的挑战。瑞兹维鲁他胺,一种来自中国的新型雄激素受体拮抗剂，已经显示出早期的希望；然而，其真实世界的有效性和安全性需要进一步的证据.本病例系列评估瑞维鲁胺联合雄激素剥夺治疗（ADT）的初步临床结果，重点关注4例前列腺癌不同阶段的PSA反应和放射学发现。
案例1详述了一名68岁男性，低量mHSPC表现出积极的治疗反应，通过降低PSA水平和改善射线照相结果来证明，尽管经历了与药物有关的轻微副作用。案例2描述了一名71岁的男性，患有大量mHSPC，结果良好，肿瘤大小或转移扩散无明显变化，对药物无不良反应。病例3涉及一名55岁的男性，患有局部晚期前列腺癌，他们看到PSA水平降低和肿瘤体积略有减少，但仍有膀胱受累。基因检测显示无明显突变。病例4显示一名74岁男性患有广泛的转移性疾病，最初对治疗有反应，但后来表现出疾病进展和ATM基因突变。信号转向转移性去势抵抗性前列腺癌（mCRPC）。这一发现强调了基因检测在指导未来治疗方面的关键作用。建议使用奥拉帕尼或化疗等疗法。
■Rezvilutamide在mHSPC和局部晚期前列腺癌的治疗中显示出潜在的益处，通常具有温和的安全性。最初的积极回应，特别是PSA下降和影像学进展，很有希望。然而，不同的反应，特别是关于基因突变，强调定制治疗方法的必要性。由于队列小，随访时间短，更广泛的研究人群和长期监测对于最终确定瑞维鲁胺的益处和安全性至关重要.利用遗传见解是改善晚期前列腺癌患者的治疗决策和提高预后的关键。
案例1详述了一名68岁男性，低量mHSPC表现出积极的治疗反应，通过降低PSA水平和改善射线照相结果来证明，尽管经历了与药物有关的轻微副作用。案例2描述了一名71岁的男性，患有大量mHSPC，结果良好，肿瘤大小或转移扩散无明显变化，对药物无不良反应。病例3涉及一名55岁的男性，患有局部晚期前列腺癌，他们看到PSA水平降低和肿瘤体积略有减少，但仍有膀胱受累。基因检测显示无明显突变。病例4显示一名74岁男性患有广泛的转移性疾病，最初对治疗有反应，但后来表现出疾病进展和ATM基因突变。信号转向转移性去势抵抗性前列腺癌（mCRPC）。这一发现强调了基因检测在指导未来治疗方面的关键作用。建议使用奥拉帕尼或化疗等疗法。
■Rezvilutamide在mHSPC和局部晚期前列腺癌的治疗中显示出潜在的益处，通常具有温和的安全性。最初的积极回应，特别是PSA下降和影像学进展，很有希望。然而，不同的反应，特别是关于基因突变，强调定制治疗方法的必要性。由于队列小，随访时间短，更广泛的研究人群和长期监测对于最终确定瑞维鲁胺的益处和安全性至关重要.利用遗传见解是改善晚期前列腺癌患者的治疗决策和提高预后的关键。
